Pranlukast hydrate in the treatment of pediatric bronchial asthma
Shigemi Yoshihara Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan Abstract: Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-07-01
|
| Series: | Pediatric Health, Medicine and Therapeutics |
| Online Access: | http://www.dovepress.com/pranlukast-hydrate-in-the-treatment-of-pediatric-bronchial-asthma-a13612 |
| _version_ | 1811237645039173632 |
|---|---|
| author | Yoshihara S |
| author_facet | Yoshihara S |
| author_sort | Yoshihara S |
| collection | DOAJ |
| description | Shigemi Yoshihara Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan Abstract: Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatric patients. In a 4-week, dose-finding study, a dose-dependent improvement in lung function was observed in pediatric patients with asthma at an optimal dose of 5.1–10 mg/kg/day. In a comparative, randomized, double-blind, 4-week multicenter trial, pranlukast dry syrup 7 mg/kg/day achieved significantly better final overall improvement (71.4%) versus oxatomide 1 mg/kg/day (37.2%) in pediatric patients older than one year with asthma. In two 12-week, open-label trials and in a long-term open-label trial of treatment for up to 24 months, pranlukast dry syrup improved asthma control over baseline values. In a prospective post-marketing surveillance study and a long-term follow-up study, the safety and efficacy of pranlukast dry syrup was confirmed in infants younger than one year with bronchial asthma. In a 4-week, open-label trial, pranlukast dry syrup improved overall health-related quality of life and physical and emotional domain scores over baseline in pediatric patients with asthma. In a randomized, multicenter, double-blind, placebo-controlled, two-period crossover trial, pranlukast dry syrup significantly inhibited exercise-induced bronchospasm in children with asthma compared with placebo. In a modified Childhood Asthma Control Test, pranlukast dry syrup was significantly more effective in controlling asthma in patients younger than 4 years with the common cold. These findings show that pranlukast is useful and beneficial for treating pediatric patients with bronchial asthma. Keywords: pranlukast, leukotriene receptor antagonist, pediatric asthma |
| first_indexed | 2024-04-12T12:26:41Z |
| format | Article |
| id | doaj.art-abd1fe23eddd48d2b11d45bfb68b5362 |
| institution | Directory Open Access Journal |
| issn | 1179-9927 |
| language | English |
| last_indexed | 2024-04-12T12:26:41Z |
| publishDate | 2013-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pediatric Health, Medicine and Therapeutics |
| spelling | doaj.art-abd1fe23eddd48d2b11d45bfb68b53622022-12-22T03:33:08ZengDove Medical PressPediatric Health, Medicine and Therapeutics1179-99272013-07-012013default5563Pranlukast hydrate in the treatment of pediatric bronchial asthmaYoshihara SShigemi Yoshihara Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan Abstract: Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatric patients. In a 4-week, dose-finding study, a dose-dependent improvement in lung function was observed in pediatric patients with asthma at an optimal dose of 5.1–10 mg/kg/day. In a comparative, randomized, double-blind, 4-week multicenter trial, pranlukast dry syrup 7 mg/kg/day achieved significantly better final overall improvement (71.4%) versus oxatomide 1 mg/kg/day (37.2%) in pediatric patients older than one year with asthma. In two 12-week, open-label trials and in a long-term open-label trial of treatment for up to 24 months, pranlukast dry syrup improved asthma control over baseline values. In a prospective post-marketing surveillance study and a long-term follow-up study, the safety and efficacy of pranlukast dry syrup was confirmed in infants younger than one year with bronchial asthma. In a 4-week, open-label trial, pranlukast dry syrup improved overall health-related quality of life and physical and emotional domain scores over baseline in pediatric patients with asthma. In a randomized, multicenter, double-blind, placebo-controlled, two-period crossover trial, pranlukast dry syrup significantly inhibited exercise-induced bronchospasm in children with asthma compared with placebo. In a modified Childhood Asthma Control Test, pranlukast dry syrup was significantly more effective in controlling asthma in patients younger than 4 years with the common cold. These findings show that pranlukast is useful and beneficial for treating pediatric patients with bronchial asthma. Keywords: pranlukast, leukotriene receptor antagonist, pediatric asthmahttp://www.dovepress.com/pranlukast-hydrate-in-the-treatment-of-pediatric-bronchial-asthma-a13612 |
| spellingShingle | Yoshihara S Pranlukast hydrate in the treatment of pediatric bronchial asthma Pediatric Health, Medicine and Therapeutics |
| title | Pranlukast hydrate in the treatment of pediatric bronchial asthma |
| title_full | Pranlukast hydrate in the treatment of pediatric bronchial asthma |
| title_fullStr | Pranlukast hydrate in the treatment of pediatric bronchial asthma |
| title_full_unstemmed | Pranlukast hydrate in the treatment of pediatric bronchial asthma |
| title_short | Pranlukast hydrate in the treatment of pediatric bronchial asthma |
| title_sort | pranlukast hydrate in the treatment of pediatric bronchial asthma |
| url | http://www.dovepress.com/pranlukast-hydrate-in-the-treatment-of-pediatric-bronchial-asthma-a13612 |
| work_keys_str_mv | AT yoshiharas pranlukasthydrateinthetreatmentofpediatricbronchialasthma |